Literature DB >> 16174286

Role of aldosterone in diabetic nephropathy.

Dae Ryong Cha1, Young Sun Kang, Sang Youb Han, Yi Hwa Jee, Kum Hyun Han, Hyoung Kyu Kim, Jee Young Han, Young Sik Kim.   

Abstract

In the last 10 years, many studies have focused on the non-classical action of aldosterone. One of the most important new aspects of aldosterone is its pathogenic role as proinflammatory and profibrotic molecules. It has been reported that aldosterone induces myocardial fibrosis and vascular inflammation through up-regulation of various proinflammatory and profibrotic cytokines. We investigated the effect of aldosterone and spironolactone, which is a non-selective mineralocorticoid receptor antagonist, on monocyte chemoattractant peptide (MCP-1) and collagen synthesis in cultured mesangial and tubular epithelial cells. In addition, to evaluate the effect of spironolactone on diabetic nephropathy, we used Otsuka Long-Evans Tokushima Fatty (OLETF) rats which are known type 2 diabetic animal models. Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure. However, spironolactone therapy significantly inhibited urinary albumin and MCP-1 excretion. Spironolactone treatment also suppressed renal mRNA expression for MCP-1, macrophage migration inhibitory factor (MIF) as well as intrarenal protein synthesis for ED-1 and MIF. Morphologically, spironolactone treatment significantly prevented glomerulosclerosis, collagen deposition and connective tissue growth factor (CTGF) expression in diabetic rats. In cultured cell experiments, aldosterone directly increased the MCP-1, collagen secretion and spironolactone treatment abolished aldosterone-induced MCP-1 and collagen synthesis. Surprisingly, aldosterone treatment did not induce any significant change in TGFbeta1 gene transcription. Finally, we found that NF-kB activity was increased after stimulation with aldosterone and spironolactone therapy inhibited their activation. In addition, prior treatment with pyrrolidine dithiocarbamate (PDTC), which is a NF-KB inhibitor, inhibited aldosterone-induced MCP-1 protein secretion. These results suggest that aldosterone blockade could play a role in preventing the progression of diabetic nephropathy via anti-inflammatory and antifibrotic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174286     DOI: 10.1111/j.1440-1797.2005.00455.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  9 in total

1.  Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression.

Authors:  Er-Liang Kong; Jin-Min Zhang; Ni An; Yong Tao; Wei-Feng Yu; Fei-Xiang Wu
Journal:  J Cell Commun Signal       Date:  2018-06-07       Impact factor: 5.782

Review 2.  Lipid deposition and metaflammation in diabetic kidney disease.

Authors:  Alla Mitrofanova; Antonio M Fontanella; Sandra Merscher; Alessia Fornoni
Journal:  Curr Opin Pharmacol       Date:  2020-11-01       Impact factor: 5.547

Review 3.  Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

Authors:  Jun Panee
Journal:  Cytokine       Date:  2012-07-04       Impact factor: 3.861

4.  Increased glucocorticoid metabolism in diabetic kidney disease.

Authors:  Daniel Ackermann; Bruno Vogt; Murielle Bochud; Michel Burnier; Pierre-Yves Martin; Fred Paccaud; Georg Ehret; Idris Guessous; Belen Ponte; Menno Pruijm; Antoinette Pechère-Bertschi; Heidi Jamin; Rahel Klossner; Bernhard Dick; Markus G Mohaupt; Carine Gennari-Moser
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

5.  Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease.

Authors:  Weisong Wang; Lihua Li; Zhonghai Zhou; Junjie Gao; Yinghao Sun
Journal:  Exp Ther Med       Date:  2013-10-09       Impact factor: 2.447

6.  Effect of telmisartan and enalapril on ventricular remodeling and kidney prognosis of patients with coronary artery disease complicated with diabetic nephropathy.

Authors:  Yuyan Hou; Fucheng Zhang; Zhiqiang Liu; Shuhong Su; Xiao Wu; Zhifang Wang
Journal:  Exp Ther Med       Date:  2016-11-29       Impact factor: 2.447

7.  Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice.

Authors:  Roberto Palacios-Ramirez; Ixchel Lima-Posada; Benjamin Bonnard; Marie Genty; Amaya Fernandez-Celis; Judith Hartleib-Geschwindner; Fabienne Foufelle; Natalia Lopez-Andres; Krister Bamberg; Frederic Jaisser
Journal:  Front Physiol       Date:  2022-04-07       Impact factor: 4.755

Review 8.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008

Review 9.  NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes.

Authors:  Sachin V Suryavanshi; Yogesh A Kulkarni
Journal:  Front Pharmacol       Date:  2017-11-07       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.